Compare Canopy Growth Corp (CGC) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Deere & Company — how do they compare? Canopy Growth Corp trades at $1.04 (market cap $421.10M), while Deere & Company trades at $620.82 (market cap $166.81B). The key difference: Deere & Company is far larger — about 396.1× Canopy Growth Corp's market cap, and Deere & Company pays a 1.05% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | DE | |
|---|---|---|
Market Cap | $421.10M | $166.81B |
Sector | Health | Industrials |
52-Week High | $1.92 | $662.49 |
52-Week Low | $0.86 | $439.11 |
Enterprise Value | $378.55M | $221.63B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Deere & Company (DE) trades at $619.82, up 1.73% in the last session, reflecting positive momentum amid a bullish technical signal. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $6.55 surpassing the $5.70 forecast. However, revenue declined to $44.67 billion in 2025, and net income margin compressed to 10.33%. The stock's valuation multiples, including a P/E of 35.01, are elevated relative to historical norms, while analyst consensus leans moderate buy with a $669.79 price target.
The outlook for DE hinges on agricultural demand recovery, but near-term risks include weak North American equipment sales and margin pressure. Upside potential exists if earnings sustain beats and cost controls improve profitability, yet investors face cyclical industry exposure and high debt levels. The current price near resistance at $620 suggests cautious entry points may be prudent pending Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
